These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 27440003)

  • 21. Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome).
    Whellan DJ; Tricoci P; Chen E; Huang Z; Leibowitz D; Vranckx P; Marhefka GD; Held C; Nicolau JC; Storey RF; Ruzyllo W; Huber K; Sinnaeve P; Weiss AT; Dery JP; Moliterno DJ; Van de Werf F; Aylward PE; White HD; Armstrong PW; Wallentin L; Strony J; Harrington RA; Mahaffey KW
    J Am Coll Cardiol; 2014 Mar; 63(11):1048-57. PubMed ID: 24211500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease.
    Arif SA; D'Souza J; Gil M; Gim S
    Am J Health Syst Pharm; 2015 Oct; 72(19):1615-22. PubMed ID: 26386102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxar.
    Farag M; Patel H; Gorog DA
    Drug Des Devel Ther; 2015; 9():3801-9. PubMed ID: 26229441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coronary stent thrombosis with vorapaxar versus placebo: results from the TRA 2° P-TIMI 50 trial.
    Bonaca MP; Scirica BM; Braunwald E; Wiviott SD; O'Donoghue ML; Murphy SA; Morrow DA
    J Am Coll Cardiol; 2014 Dec; 64(22):2309-17. PubMed ID: 25465416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peripheral Revascularization in Patients With Peripheral Artery Disease With Vorapaxar: Insights From the TRA 2°P-TIMI 50 Trial.
    Bonaca MP; Creager MA; Olin J; Scirica BM; Gilchrist IC; Murphy SA; Goodrich EL; Braunwald E; Morrow DA
    JACC Cardiovasc Interv; 2016 Oct; 9(20):2157-2164. PubMed ID: 27765312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function.
    Correa S; Bonaca MP; Scirica BM; Murphy SA; Goodrich EL; Morrow DA; O'Donoghue ML
    J Thromb Thrombolysis; 2019 Apr; 47(3):353-360. PubMed ID: 30511258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2°P-TIMI 50 trial.
    Qamar A; Morrow DA; Creager MA; Scirica BM; Olin JW; Beckman JA; Murphy SA; Bonaca MP
    Vasc Med; 2020 Apr; 25(2):124-132. PubMed ID: 32000630
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial.
    Harskamp RE; Clare RM; Ambrosio G; Held C; Lokhnygina Y; Moliterno DJ; White HD; Aylward PE; Armstrong PW; Mahaffey KW; Harrington RA; Van de Werf F; Wallentin L; Strony J; Tricoci P
    Eur Heart J Acute Cardiovasc Care; 2017 Mar; 6(2):155-163. PubMed ID: 26895973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vorapaxar: emerging evidence and clinical questions in a new era of PAR-1 inhibition.
    Ungar L; Rodriguez F; Mahaffey KW
    Coron Artery Dis; 2016 Nov; 27(7):604-15. PubMed ID: 27398626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial.
    Held C; Tricoci P; Huang Z; Van de Werf F; White HD; Armstrong PW; Ambrosio G; Aylward PE; Moliterno DJ; Wallentin L; Chen E; Erkan A; Jiang L; Strony J; Harrington RA; Mahaffey KW
    Eur Heart J Acute Cardiovasc Care; 2014 Sep; 3(3):246-56. PubMed ID: 24627331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar.
    Déry JP; Mahaffey KW; Tricoci P; White HD; Podder M; Westerhout CM; Moliterno DJ; Harrington RA; Chen E; Strony J; Van de Werf F; Ziada KM; Held C; Aylward PE; Armstrong PW; Rao SV
    Catheter Cardiovasc Interv; 2016 Aug; 88(2):163-73. PubMed ID: 26698636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar.
    Cheng JW
    Vasc Health Risk Manag; 2016; 12():263-8. PubMed ID: 27366081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial.
    Tricoci P; Lokhnygina Y; Huang Z; Van de Werf F; Cornel JH; Chen E; Wallentin L; Held C; Aylward PE; Moliterno DJ; Jennings LK; White HD; Armstrong PW; Harrington RA; Strony J; Mahaffey KW
    Am Heart J; 2014 Dec; 168(6):869-77.e1. PubMed ID: 25458650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease.
    Gryka RJ; Buckley LF; Anderson SM
    Drugs R D; 2017 Mar; 17(1):65-72. PubMed ID: 28063023
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial.
    Eisen A; Bonaca MP; Jarolim P; Scirica BM; White HD; Tendera M; Dellborg M; Nicolau JC; Morais J; Fox KA; Bohula EA; Murphy SA; Braunwald E; Morrow DA
    Clin Chem; 2017 Jan; 63(1):307-315. PubMed ID: 28062625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial.
    Leonardi S; Tricoci P; White HD; Armstrong PW; Huang Z; Wallentin L; Aylward PE; Moliterno DJ; Van de Werf F; Chen E; Providencia L; Nordrehaug JE; Held C; Strony J; Rorick TL; Harrington RA; Mahaffey KW
    Eur Heart J; 2013 Jun; 34(23):1723-31. PubMed ID: 23530022
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review of vorapaxar for the prevention of atherothrombotic events.
    Wang A
    Expert Opin Pharmacother; 2015; 16(16):2509-22. PubMed ID: 26480240
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improving Outcomes in Cardiovascular Diseases: A Review on Vorapaxar.
    Chaudhary R; Mohananey A; Sharma SP; Singh S; Singh A; Kondur A
    Cardiol Rev; 2022 Sep-Oct 01; 30(5):241-246. PubMed ID: 33758122
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vorapaxar, a Protease-Activated Receptor-1 Antagonist, a Double-Edged Sword!
    Bhandari B; Mehta B
    Recent Adv Cardiovasc Drug Discov; 2014; 9(2):73-7. PubMed ID: 26104312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54).
    Bonaca MP; Goto S; Bhatt DL; Steg PG; Storey RF; Cohen M; Goodrich E; Mauri L; Ophuis TO; Ruda M; Špinar J; Seung KB; Hu D; Dalby AJ; Jensen E; Held P; Morrow DA; Braunwald E; Sabatine MS
    Circulation; 2016 Sep; 134(12):861-71. PubMed ID: 27576775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.